Beryl Drugs Current Share Price | Beryl Drugs Stock Screener
BERLDRG
Pharmaceuticals
Beryl Drugs Current Stock Price Today
Live Share Price BSE
₹23.00
▲
0.00 (0.00%)
As of August 18, 2026, the live Beryl Drugs share price (BSE: BERLDRG) is ₹23.00, unchanged from the previous close, with shares trading between ₹22.00 and ₹23.39 in today's trading session, and a 52-week range of ₹16.87–₹28.09.
Analyse BERLDRG share price data and track historical price performance.
Use the Beryl Drugs stock screener below to analyse P/E ratio, market cap, quarterly results, and more. Record your trades in TickJournal's free trading journal and track your portfolio performance.
Beryl Drugs Market Cap
₹11.60 Cr.
BERLDRG P/E Ratio (TTM)
18.66
Beryl Drugs P/B Ratio
1.18
EPS (TTM)
₹0.84
Dividend Yield
-
Debt to Equity
0.50
BERLDRG 52 Week High
₹28.09
Beryl Drugs 52 Week Low
₹16.87
Operating Margin
8.00%
Profit Margin
4.55%
BERLDRG Revenue (TTM)
₹22.00
EBITDA
₹2.00
Net Income
₹1.00
Total Assets
₹15.00
Total Equity
₹10.00
Beryl Drugs Current Share Price Chart
Track the current Beryl Drugs share price and stock price with an interactive chart. Analyse BERLDRG price trends, trading volume, historical performance, and volatility across different timeframes — the complete Beryl Drugs stock quote in one place.
Beryl Drugs Company Profile - Fundamental Screener
Screen Beryl Drugs company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics
for BERLDRG shares.
Sector
Healthcare
Industry
Pharmaceuticals
Sub-Sector
Pharmaceuticals
Segment
E
ISIN
INE415H01017
Beryl Drugs Balance Sheet Screener
Screen BERLDRG balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation
metrics.
| Item | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||
| Total Assets | 15 | 16 | 18 | 18 | 18 | 19 | 17 | 15 | 11 | 10 |
| Current Assets | 7 | 9 | 10 | 10 | 11 | 10 | 8 | 5 | 7 | 7 |
| Fixed Assets | 7 | 6 | 6 | 6 | 6 | 8 | 9 | 2 | 2 | 2 |
| Liabilities | ||||||||||
| Total Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Current Liabilities | 1 | 2 | 3 | 3 | 2 | 3 | 3 | 2 | 0 | 0 |
| Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Shareholders' Equity | ||||||||||
| Total Equity | 10 | 10 | 9 | 8 | 7 | 8 | 8 | 8 | 7 | 6 |
| Share Capital | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 |
| Reserves & Surplus | 5 | 4 | 4 | 3 | 2 | 3 | 3 | 2 | 2 | 1 |
Beryl Drugs Income Statement Screener - Profit & Revenue Analysis
Screen Beryl Drugs income statement and profit fundamentals.
Analyze BERLDRG quarterly results,
revenue growth, EBITDA, net profit margins, and EPS using TickJournal's fundamental screener for Beryl Drugs share price evaluation.
| Item | None-None | 2026-March | 2025-March | 2024-March | 2023-March | 2022-March | 2021-March | 2020-March | 2019-March | 2018-March | 2017-March | 2016-March | 2015-March |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 22 | 19 | 23 | 27 | 27 | 15 | 14 | 13 | 13 | 16 | 11 | 14 | 14 |
| Expenses | 20 | 17 | 20 | 25 | 25 | 14 | 13 | 12 | 12 | 14 | 11 | 13 | 13 |
| EBITDA | 2 | 2 | 3 | 3 | 2 | 1 | 2 | 1 | 1 | 2 | 0 | 1 | 1 |
| Operating Profit % | 8.00% | 10.00% | 6.00% | 9.00% | 7.00% | 3.00% | 10.00% | 7.00% | 8.00% | 7.00% | -1.00% | 4.00% | 6.00% |
| Depreciation | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 1 |
| Interest | 0 | 0 | 1 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit Before Tax | 1 | 1 | 1 | 1 | 1 | -1 | 0 | 0 | 1 | 1 | 0 | 0 | 0 |
| Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Profit | 1 | 0 | 1 | 1 | 1 | -1 | 0 | 0 | 1 | 1 | 0 | 0 | 0 |
| EPS | 1.20 | 0.84 | 1.14 | 1.52 | 1.51 | -1.30 | 0.47 | 0.09 | 1.16 | 1.96 | -0.88 | 0.33 | 0.17 |
Beryl Drugs Cash Flow Screener - Liquidity Fundamentals
Screen BERLDRG cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price
strength assessment.
| Item | 2025-March | 2024-March | 2023-March | 2022-March | 2021-March | 2020-March | 2019-March | 2018-March | 2017-March | 2016-March |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | 3 | 1 | 3 | 0 | 0 | 0 | 3 | 0 | 0 | 0 |
| Investing Activities | 0 | -1 | -1 | 1 | 0 | -2 | -5 | 0 | 0 | 0 |
| Financing Activities | -2 | 0 | -1 | 0 | -1 | 2 | 2 | 0 | 0 | 0 |
| Net Cash Flow | 1 | 0 | 0 | 0 | 0 | 0 | 0 | -1 | 1 | 0 |
Beryl Drugs Shareholding Pattern Screener
See Beryl Drugs shareholding pattern with promoter, FII, and DII holdings.
Check Beryl Drugs promoter holding and ownership changes for BERLDRG on TickJournal.
| Item | 2026-Mar | 2026-Jun | 2025-Mar | 2025-Jun | 2025-Sept | 2025-Dec | 2024-Mar | 2024-Jun |
|---|---|---|---|---|---|---|---|---|
| Promoter Holding | 27.48% | 27.82% | 26.38% | 26.38% | 26.38% | 26.38% | 26.38% | 26.38% |
| FII Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| DII Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Govt Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Public Holding | 64.94% | 63.56% | 68.53% | 68.69% | 68.71% | 66.25% | 66.26% | 68.06% |
| Other Holding | 7.59% | 8.62% | 5.08% | 4.93% | 4.91% | 7.37% | 7.35% | 5.55% |
| Shareholder Count | 7,349 | 7,309 | 7,431 | 7,415 | 7,446 | 7,409 | 7,257 | 7,325 |
Beryl Drugs Share Dividend Screener - Share Yield Analysis
Check Beryl Drugs dividend history with payout and yield data.
View Beryl Drugs dividend details including ex-dates and amounts for BERLDRG stock.
Beryl Drugs Stock Index Membership
See which indices include Beryl Drugs stock.
Check BERLDRG index membership in NIFTY 50, SENSEX, and other indices on TickJournal.
Beryl Drugs Market Events Screener - Corporate Actions
Get Beryl Drugs corporate actions including splits, bonuses, and buybacks.
Check Beryl Drugs stock events that may affect BERLDRG share price.
| Announcement Date | Record Date | Event Type | Information | Price Impact |
|---|---|---|---|---|
| 2026-08-11 | 2026-08-11 | Quarterly Result Announcement | NA | 8.77% |
| 2026-05-28 | 2026-05-28 | Quarterly Result Announcement | NA | -1.24% |
| 2026-05-11 | 2026-05-11 | Extraordinary General Meeting | NA | 6.79% |
| 2026-03-16 | 2026-03-16 | Extraordinary General Meeting | NA | -6.91% |
| 2026-02-09 | 2026-02-09 | Quarterly Result Announcement | NA | -1.32% |
| 2025-11-13 | 2025-11-13 | Quarterly Result Announcement | NA | 1.70% |
| 2025-09-30 | 2025-09-30 | Annual General Meeting | NA | -16.04% |
| 2025-08-07 | 2025-08-07 | Quarterly Result Announcement | NA | -3.22% |
| 2025-05-30 | 2025-05-30 | Quarterly Result Announcement | NA | -4.64% |
| 2025-02-08 | 2025-02-08 | Quarterly Result Announcement | NA | -6.59% |
| 2024-11-13 | 2024-11-13 | Quarterly Result Announcement | NA | 0.30% |
| 2024-09-30 | 2024-09-30 | Annual General Meeting | NA | -1.84% |
Beryl Drugs Competitors Screener - Peer Comparison
Screen BERLDRG competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance for better
stock selection.
| Company | Market Cap | P/E Ratio | Revenue | YoY Growth | Net Profit | RSI |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical | 463,072 | 38.12 | 61,674 | 12.69% | 11,565 | 47.09 |
| Divis Laboratories | 225,038 | 77.15 | 11,067 | 13.95% | 2,568 | 71.85 |
| Torrent Pharmaceuticals | 183,832 | 85.40 | 13,886 | 20.34% | 2,138 | 45.42 |
| Cipla | 117,138 | 34.91 | 29,045 | 2.24% | 3,870 | 50.74 |
| Zydus Life Science | 114,228 | 24.76 | 27,658 | 17.64% | 5,026 | 50.68 |
| Lupin | 102,192 | 18.41 | 29,039 | 26.75% | 5,356 | 30.04 |
| Dr Reddys Laboratories | 100,160 | 31.52 | 35,059 | 3.90% | 4,158 | 49.18 |
| Mankind Pharma | 100,160 | 48.34 | 14,636 | 14.85% | 1,938 | 43.34 |
| Laurus Labs | 96,489 | 89.94 | 6,868 | 22.01% | 890 | 61.64 |
| Aurobindo Pharma | 93,332 | 25.95 | 34,145 | 5.56% | 3,503 | 55.68 |
Beryl Drugs Company Announcements - News Screener
Screen BERLDRG latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis.
| Date | Update | Actions |
|---|---|---|
| 2026-08-16 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2026-08-14 | UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE 2026 | - |
| 2026-08-14 | Board Meeting Outcome for OUTCOME OF BOARD MEETING | - |
| 2026-08-05 | Board Meeting Intimation for Consider And Approve The Unaudited Financial Results For The Quarter Ended 30Th June 2026 | - |
| 2026-07-21 | Intimation Regarding Temporary Unavailability Of The Companys Website Due To An Unexpected Technical Issue | - |
| 2026-07-06 | Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 | - |
| 2026-07-06 | Compliance-57 (5) : intimation after the end of quarter | - |
| 2026-06-30 | Closure of Trading Window | - |
| 2026-06-29 | Disclosures under Reg. 29(1) of SEBI (SAST) Regulations 2011 | - |
| 2026-06-16 | Announcement under Regulation 30 (LODR)-Change in Registered Office Address | - |
| 2026-06-16 | Board Meeting Outcome for OUTCOME OF BOARD MEETING | - |
| 2026-06-12 | Disclosures under Reg. 29(1) of SEBI (SAST) Regulations 2011 | - |
| 2026-06-11 | Disclosures under Reg. 29(1) of SEBI (SAST) Regulations 2011 | - |
| 2026-06-10 | Disclosures under Reg. 29(1) of SEBI (SAST) Regulations 2011 | - |
| 2026-06-08 | Board Meeting Intimation for CHANGE IN REGISTERED OFFICE OF THE COMPANY | - |
| 2026-06-08 | Disclosures under Reg. 29(1) of SEBI (SAST) Regulations 2011 | - |
| 2026-05-29 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2026-05-28 | AUDITED FINANCIAL RESULTS FOR THE YEAR ENDED 31ST MARCH 2026 | - |
| 2026-05-28 | Board Meeting Outcome for OUTCOME OF BOARD MEETING | - |
| 2026-05-20 | Board Meeting Intimation for Consider And Approve The Audited Financial Statement Including Balance Sheet As At 31St March 2026 Statement Of Profit And Loss Cash Flow And Notes Thereon For The Year Ended 31St March 2026. | - |